Michael Sen

Michael Sen became CEO of Fresenius in October 2022, tasked with restructuring a sprawling healthcare conglomerate that had underperformed for years. The most significant move was the deconsolidation of Fresenius Medical Care (FMC) — the world's largest kidney dialysis provider — transforming Fresenius's ownership from an operating parent into a financial investor with a minority stake. This unlocked value by simplifying the group structure and allowing each company to pursue independent strategies. The "new" Fresenius focuses on two core businesses: Fresenius Kabi (a global leader in clinical nutrition, intravenous drugs, biosimilars, and medical devices — serving hospitals and healthcare systems worldwide) and Helios (Europe's largest private hospital operator, running over 100 hospitals in Germany through Helios Germany and in Spain through Quirónsalud, Spain's largest private hospital network). Kabi benefits from the growth of hospital-administered drugs, IV nutrition, and biosimilars, while Helios benefits from aging demographics and the trend toward hospital privatization in Europe. Sen's restructuring also includes operational efficiency programs targeting €600+ million in productivity improvements. Key stock drivers include Kabi organic revenue growth (particularly biosimilars and MedTech), Helios hospital admissions and case mix, German hospital reform legislation, Quirónsalud performance, Fresenius Medical Care stake value, operating margin improvement, debt reduction, and the overall trend toward private healthcare in European markets.